English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/155101
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia

AutorRuiz-Llorente, Lidia ; Gallardo-Vara, Eunate ; Rossi, Elisa; Smadja, David M.; Botella, Luisa María ; Bernabéu, Carmelo
Palabras claveHHT
Endoglin
ALK1
Haploinsufficiency
Bleeding
Angiogenesis
AVM
Bevacizumab
Thalidomide
Fecha de publicaciónoct-2017
EditorTaylor & Francis
CitaciónExpert Opin Ther Targets. 21(10):933-947 (2017)
ResumenIntroduction: Hereditary Haemorrhagic Telangiectasia (HHT) is as an autosomal dominant trait characterized by frequent nose bleeds, mucocutaneous telangiectases, arteriovenous malformations (AVMs) of the lung, liver and brain, and gastrointestinal bleedings due to telangiectases. HHT is originated by mutations in genes whose encoded proteins are involved in the transforming growth factor β (TGF-β) family signalling of vascular endothelial cells. In spite of the great advances in the diagnosis as well as in the molecular, cellular and animal models of HHT, the current treatments remain just at the palliative level.
Areas covered: Pathogenic mutations in genes coding for the TGF-β receptors endoglin (ENG) (HHT1) or the activin receptor-like kinase-1 (ACVRL1 or ALK1) (HHT2), are responsible for more than 80% of patients with HHT. Therefore, ENG and ALK1 are the main potential therapeutic targets for HHT and the focus of this review. The current status of the preclinical and clinical studies, including the antiangiogenic strategy, have been addressed.
Expert opinion: Endoglin and ALK1 are attractive therapeutic targets in HHT. Because haploinsufficiency is the pathogenic mechanism in HHT, several therapeutic approaches able to enhance protein expression and/or function of endoglin and ALK1 are keys to find novel and efficient treatments for the disease.
Versión del editorhttp://dx.doi.org/10.1080/14728222.2017.1365839
URIhttp://hdl.handle.net/10261/155101
DOI10.1080/14728222.2017.1365839
ISSN1472-8222
E-ISSN1744-7631
Aparece en las colecciones: (CIB) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Ruiz-Llorente EOTT 2017 .pdfArtículo principal2,74 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.